Imidazo[1,2- a ]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges
ACS Omega · 11.08.2026 · 11 (31) · 45657-45678
DOI: 10.1021/acsomega.6c07566 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Omega, online erschienen am 31.07.2026. Verfasst von Giorgio Antoniolli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemistry, University of São Paulo, São Paulo, São Paulo 05508-000, Brazil. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Imidazo[1,2-a]pyridine derivatives are privileged scaffolds in medicinal chemistry due to their structural versatility, favorable physicochemical properties, and broad pharmacological relevance. Their fused heterocyclic framework enables extensive functionalization while preserving conformational rigidity and optimal heteroatom distribution, making this core highly attractive for drug discovery. This systematic review summarizes recent advances (last 5 years) in the synthesis, structural diversification, and biological evaluation of imidazo[1,2-a]pyridine-based compounds. A comprehensive literature search was performed using the Scopus and Web of Science databases, focusing on studies reporting relevant biological data. The reviewed derivatives display diverse pharmacological activities, including anticancer, antimicrobial, antitubercular, antifungal, antiparasitic, neuroactive, anti-inflammatory, antidiabetic, and ferroptosis-modulating effects. Emphasis is placed on structure–activity relationships, scaffold-hopping strategies, and emerging hybrid designs. Despite promising in vitro potency against multiple therapeutic targets, important limitations remain. Many compounds still lack in vivo validation, pharmacokinetic characterization, and ADME/Tox optimization, restricting their progression toward preclinical development. In addition, structural exploration remains concentrated on conventional substitution patterns, underscoring the need for broader bioisosteric and fragment-based approaches. Overall, this review consolidates recent advances, highlights critical knowledge gaps, and outlines future directions for the rational development of imidazo[1,2-a]pyridine-based therapeutics.
Autor:innen und Institutionen
- Institute of Chemistry, University of São Paulo, São Paulo, São Paulo 05508-000, Brazil.
- Center for Natural and Human Sciences, Federal University of ABC, Santo André, São Paulo 09210-170, Brazil.
- Integrated Biotechnology Center, University of Mogi Das Cruzes, Mogi Das Cruzes, São Paulo 08780-911, Brazil.
ORCID-Profile: Giorgio Antoniolli, Tiago Rodrigues
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Antoniolli, G., Chaguri, R., Grabauskas, L. A., Arruda, D. C., & Rodrigues, T. (2026). Imidazo[1,2- a ]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges. ACS Omega, 11(31), 45657-45678. https://doi.org/10.1021/acsomega.6c07566
Vancouver
Antoniolli G, Chaguri R, Grabauskas LA, Arruda DC, Rodrigues T. Imidazo[1,2- a ]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges. ACS Omega. 2026;11(31):45657-45678. doi:10.1021/acsomega.6c07566
BibTeX
@article{Antoniolli2026,
author = {Antoniolli, Giorgio and Chaguri, Rebeca and Grabauskas, Lorraine Alves and Arruda, Denise Costa and Rodrigues, Tiago},
title = {Imidazo[1,2- a ]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {31},
pages = {45657--45678},
doi = {10.1021/acsomega.6c07566}
}
EUVIMED